Safety of Switching From Rituximab to Ocrelizumab in MS Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.
Epistemonikos ID: 46f5e94f6249e31ea0ffeaca1f90ef857ba0f119
First added on: May 20, 2024